Clinical Trials

/Clinical Trials

Erleada- New Treatment for Non-Metastatic Castrate Resistant Prostate Cancer

Erleada (apalutamide) has just received FDA approval as a drug for treating men with non-metastatic castration-resistant prostate cancer.   The proper pronunciation is Er ( Errr), (Like Her without the h) ) (lee) (long E) da. Now, repeat after me, "Erleada!" It's a pill that you take - I believe - four times a [...]

Apalutamide Looking Good as Treatment for Non-Metastatic Castrate Resistant Prostate Cancer

Non-Metastatic Castrate Resistant Prostate Cancer (nmCRPC)  usually leads to metastatic prostate cancer and death. There are no approved treatments for nmCRPC. Apalutamide is a taken-by-mouth androgen receptor inhibitor with antitumor activity in CRPC. There's a much talked and written about clinical trial called, SPARTAN, that investigated how well Apalutamide works on maintaining metastasis-free survival (MFS) [...]

New Investigational Treatment Instead of Active Surveillance & Maybe for Distant Tumors

Today’s post is not directly an advanced prostate cancer post, but more about a new potential and very interesting treatment on the horizon for men with prostate cancer that might otherwise be considered for active surveillance. According to the researchers who have been working on the treatment protocol, it is "truly transformative". This is not [...]

Expanding the Role of Radium-223 (Xofigo)

One of the newer drugs and one that has recently had great air play is the bone targeting radiopharmaceutical drug radium-223 or Xofigo. Currently, it is approved for men with castrate resistant prostate cancer with bone metastases. The problem is that currently Xofigo is only approved for one round of treatment using 6 monthly infusions. [...]

Early Hormone Therapy In Men With A Rising PSA Live Longer Then Men Who Delay Therapy – A Phase 3 Trial

The standard of care is to offer androgen deprivation therapy (ADT) to men with prostate cancer who have a rising prostate specific antigen (PSA) after an attempt to cure their cancer with primary therapy that has failed (PSA relapse) or in men who are considered not suitable for curative treatment. The question is what is [...]

Understanding Prostate Cancer Clinical Trials – Types and Stages

The decision to enroll in a clinical trial should involve a discussion between the person with prostate cancer and that individual’s physician. Your participation should depend on many factors, including your motivation for enrolling in a trial, the stage of your prostate cancer, and the trials available and its phase. When you decide to enroll in a clinical [...]

Recurring Prostate Cancer- What ADT Treatment Schedule Is Superior?

 One of the many constantly recurring topics that we discuss is over the efficacy of intermittent hormone deprivation therapy (IAD) as opposed to continuous hormone deprivation therapy (CAD). Which therapy is better has been debated for at least ten years. The debate still rages over the question of efficacy, or survival as well as the [...]

Belfast Clinical Trial Combining Two Radio-Therapies For Men With Advanced Prostate Cancer

Researchers at Queen’s University in Belfast along with the Belfast Trust are conducting a clinical trial evaluating the combination of two radiotherapy treatments, Radium 223 and Pelvic Radiation using Volumetric Modulated Arc Therapy (VMAT) in men with bone positive advanced prostate cancer. The trial, being called ADRRAD trial, involves combining androgen deprivation therapy (ADT) along [...]

A new Trend – Chemotherapy for Metastatic Castrate-Sensitive Prostate Cancer

Prostate cancer treatment will change as we incorporate new studies into our clinical practice. One of the major emerging new trends is the earlier use of chemotherapy with androgen therapy (ADT) in men, including men who are still hormone responsive. This changing trend comes from the results from there pivotal randomized phase III trials: GETUG15, [...]

Why I Believe Xtandi Is Superior To Zytiga

I believe that Xtandi (enzalutamide) is a superior drug compared to Zytiga (abiraterone). Here's why. The phase III trials for both Xtandi and Zytiga were very similar to each other. In both trials investigators measured the percentage of men who progressed or died against placebo. In this very important measurement Xtandi blew Zytiga out of the [...]